Source link : https://www.newshealth.biz/health-news/all-oral-therapy-promising-in-higher-risk-mds-cmml/
An all-oral combination therapy appeared to show promising activity for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with acceptable safety, according to results from a small phase I/II study. At a median follow-up of 10.8 months among 39 patients, the overall response rate was 95% with the combination of decitabine plus […]
Author : News Health
Publish date : 2024-02-05 14:49:22
Copyright for syndicated content belongs to the linked Source.